Dixit Subhal B, Zirpe Kapil G, Kulkarni Atul P, Chaudhry Dhruva, Govil Deepak, Mehta Yatin, Jog Sameer A, Khatib Khalid I, Pandit Rahul A, Samavedam Srinivas, Rangappa Pradeep, Bandopadhyay Susruta, Shrivastav Om, Mhatre Ujwala
Sanjeevan and MJM Hospital, Pune, Maharashtra, India.
Neuro Trauma Unit, Grant Medical Foundation, Pune, Maharashtra, India.
Indian J Crit Care Med. 2020 Sep;24(9):838-846. doi: 10.5005/jp-journals-10071-23470.
The coronavirus disease-2019 (COVID-19) pandemic has affected millions of people worldwide. As our understanding of the disease is evolving, our approach to the patient management is also changing swiftly. Available new evidence is helping us take radical decisions in COVID-19 management. We searched for inclusion of the published literature on treatment of COVID-19 from around the globe. All relevant evidences available till the time of submission of this article were briefly discussed. Once advised as blanket therapy for all patients, recent reports of hydroxychloroquine with or without azithromycin indicated no potential benefit and use of such combination may increase the risk of arrhythmias. Clinical evidence with newer antivirals such as remdesivir and favipiravir is promising that can hasten the patient recovery and reduce the mortality. With steroids, evidence is much clear in that it should be used in low dose and for short period not extending beyond 7 days in moderate to severe hospitalized patients. Low-molecular-weight heparin should be initiated in all hospitalized COVID-19 patients and dose should be based on the coagulation profile and risk of thromboembolism. Immunomodulatory drugs such tocilizumab may be considered for severe and critically ill patients to improve the outcomes. Though ulinastatin can be a potential alternative immunomodulator, there is lack of clinical evidence on its usage in COVID-19. Convalescent plasma therapy can be potentially lifesaving in critically ill patients. However, there is need to generate further evidence with various such therapies. Though availability of a potent vaccine is awaited, current treatment of COVID-19 is based on available therapies, which is guided by the evidence. In this review, we discuss the potential treatments available around the globe with current evidence on each of such treatments. Dixit SB, Zirpe KG, Kulkarni AP, Chaudhry D, Govil D, Mehta Y, Current Approaches to COVID-19: Therapy and Prevention. Indian J Crit Care Med 2020;24(9):838-846.
2019冠状病毒病(COVID-19)大流行已影响全球数百万人。随着我们对该疾病的认识不断发展,我们对患者的管理方法也在迅速变化。现有的新证据有助于我们在COVID-19管理中做出根本性决策。我们检索了全球范围内已发表的关于COVID-19治疗的文献。在提交本文时,对所有可用的相关证据进行了简要讨论。羟氯喹啉无论是否联合阿奇霉素,曾被建议作为所有患者的全面治疗方法,但最近的报告表明其无潜在益处,且使用这种联合用药可能会增加心律失常的风险。瑞德西韦和法匹拉韦等新型抗病毒药物的临床证据显示,有望加速患者康复并降低死亡率。关于类固醇,证据更为明确,即对于中重度住院患者,应采用低剂量且短期使用,不超过7天。所有住院的COVID-19患者都应开始使用低分子量肝素,剂量应根据凝血情况和血栓栓塞风险来确定。对于重症和危重症患者,可考虑使用托珠单抗等免疫调节药物以改善预后。虽然乌司他丁可能是一种潜在的替代免疫调节剂,但缺乏其在COVID-19中使用的临床证据。康复期血浆治疗对危重症患者可能具有潜在的救命作用。然而,需要通过各种此类治疗方法来产生更多证据。尽管人们期待着有有效的疫苗,但目前COVID-19的治疗是基于现有疗法,并以证据为指导。在本综述中,我们讨论了全球范围内可用的潜在治疗方法以及每种治疗方法的当前证据。 迪克西特·S·B、齐尔佩·K·G、库尔卡尼·A·P、乔杜里·D、戈维尔·D、梅塔·Y,《COVID-19的当前治疗方法:治疗与预防》。《印度重症监护医学杂志》2020年;24(9):838 - 846。